

## QVance Announces Partnership with Royale International to Drive Innovation in End-to-End Cell and Gene Therapy Cold Chain Distribution and Quality Control

QVance has today announced that it has entered into a partnership with Royale International, a global leader in logistics and supply chain management. This collaboration marks a significant milestone in the development of end-to-end cold chain distribution and quality control analytical services solutions for the cell and gene therapy sector.

The partnership combines Royale International's extensive expertise in international shipping and logistics management with QVance's innovative solutions in quality analytical services for advanced therapies. Together, the two companies aim to address the need for personalised services for drug developers and manufacturers in the cold chain handling and release of cell and gene therapies across the Nordics and Europe.

“We are thrilled to partner with Royale International and address the need for cold chain solutions throughout the manufacturing and release of cell and gene therapy products,” said Lindsay Davies, co-founder of QVance. “Royale International’s personal approach to handling of drug products during storage and transport, and their recognition of the need to offer bespoke solutions, complements our ethos at QVance, to put the customer and their product’s quality first. We recognise that with advanced therapies there is a need to be innovative in establishing solutions for quality control and standardised handling, and that a one size fits all approach is not suitable for our customers.”

“Today marks the beginning of an exciting new chapter for Royale International as we embark on this partnership with QVance. As the advanced therapy landscape continues to evolve and expand, the need for cold chain solutions that are fit for purpose for our clients are growing. The core values of our company are centric on the customer and providing tailored solutions to their needs through shared experience, innovation and collaboration. Quality forms an integral part of these solutions and bringing Royale International together with QVance demonstrates our recognition of this,” said Søren Holm Knudsen, Regional Head, Life Science – Europe from The Royale International Group.

QVance and Royale International will begin implementing joint initiatives immediately, with the launch of QVance at ATMP Sweden in Malmö on November 25th 2024.

For more information about the partnership and future developments, please contact:

Lindsay Davies



**QVance AB**

**Email: [info@qvance.se](mailto:info@qvance.se)**

**Website: [www.qvance.se](http://www.qvance.se)**

**LinkedIn <https://www.linkedin.com/company/qvance/>**

**QVance AB is the daughter company of NextCell Pharma AB**

**For more information regarding NextCell Pharma please contact**

**Mathias Svahn, CEO**

**Patrik Fagerholm, CFO**

**Tel: +46 8 735 55 95**

**E-mail: [info@nextcellpharma.com](mailto:info@nextcellpharma.com)**

**Website: [www.nextcellpharma.com](http://www.nextcellpharma.com)**

**LinkedIn: <https://www.linkedin.com/NextCell-Pharma>**

**Twitter: <https://twitter.com/NextCellPharma>**

**Certified Adviser**

**FNCA Sweden AB is assigned as Certified Adviser.**

**About QVance AB**

**QVance is a quality analytics service provider for advanced therapies. The company's vision is to be a one-stop analytics service supporting customers throughout development and drug product lifecycle.**